A pooled analysis of nine early-phase trials of trastuzumab deruxtecan monotherapy has identified an incidence of drug-related interstitial lung disease/pneumonitis of 15.4%.

medwireNews : The US FDA has approved fam-trastuzumab deruxtecan-nxki (T-DXd) for the treatment of HER2-low breast cancer and also for HER2 -mutant non-small-cell lung cancer (NSCLC).

medwireNews : The EMA has recommended changes to the indications for the PARP inhibitor olaparib and the antibody–drug conjugate trastuzumab deruxtecan in breast cancer.

Incidence and severity of trastuzumab deruxtecan-induced interstitial lung disease/pneumonitis are variable among different malignancies.

The response to trastuzumab deruxtecan in patients with metastatic breast cancer differs significantly by tumoral levels of HER2 expression, indicate results from the DAISY trial.

The antibody–drug conjugate trastuzumab deruxtecan induces a high intracranial response rate among women with HER2-positive breast cancer and active brain metastases, TUXEDO-1 study findings indicate.

medwireNews : The antibody–drug conjugate fam-trastuzumab deruxtecan-nxki has received regular approval from the US FDA for the treatment of HER2-positive advanced breast cancer.

Previously treated patients with HER2-positive metastatic breast cancer derive a significant progression-free survival benefit from trastuzumab deruxtecan relative to trastuzumab emtansine, find the DESTINY-Breast03 investigators.

Trastuzumab deruxtecan achieves durable responses in individuals who have received prior treatment for metastatic non-small-cell lung cancer harboring HER2 mutations, suggests the DESTINY-Lung01 trial.

Patients with HER2-positive metastatic breast cancer that is refractory or resistant to trastuzumab emtansine have significantly better outcomes with trastuzumab deruxtecan than a physician’s choice treatment, shows the phase 3 DESTINY-Breast02 trial.

Trastuzumab deruxtecan has demonstrated promising efficacy and tolerability in the neoadjuvant treatment of HER2-low, hormone receptor-positive early breast cancer in the TRIO-US B-12 TALENT trial.

DESTINY-Lung02 trial findings indicate that reducing the dose of trastuzumab deruxtecan can improve the antibody–drug conjugate’s toxicity profile without loss of activity in patients with previously treated, metastatic HER2 -positive non-small-cell lung cancer.

Trastuzumab deruxtecan was also recently Food and Drug Administration (FDA) approved for non-small cell lung cancer with  HER2  mutations.

Patricia LoRusso provides an independent comment on the DESTINY-Breast04 trial showing the benefit of trastuzumab deruxtecan for people with HER2-low metastatic breast cancer, and discusses the challenges involved.

Trastuzumab deruxtecan significantly improves the survival outcomes of previously treated patients with HER2-low metastatic breast cancer relative to standard chemotherapy, show DESTINY-Breast04 data.

Noting the “practice-changing results” of the DESTINY-Breast04 trial of trastuzumab deruxtecan in previously treated patients with HER2-low disease, the majority of whom were HR+, the discussant wondered about the optimal sequencing of the agents. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ESMO Congress 2022; Paris, France: 9–13 September

The guideline makes no change to the first-line treatment option of trastuzumab, pertuzumab, plus a taxane, but recommends trastuzumab deruxtecan as a new second-line option and several new options in the third and later line, including regimens with tucatinib, trastuzumab emtansine, margetuximab, and abemaciclib plus trastuzumab and fulvestrant.

Individuals with pretreated advanced non-small-cell lung cancer harboring HER2 exon 20 mutations or insertions may benefit from triple therapy with trastuzumab, pertuzumab, and docetaxel, phase 2 study findings indicate.

Promising agents under investigation are drugs targeting the HER2 pathways such as tucatinib, neratinib, pyrotinib, trastuzumab deruxtecan.

Trastuzumab deruxtecan for HER2-overexpressing NSCLC Kazuhiko Nakagawa (Kindai University Hospital, Osaka, Japan) shared data on trastuzumab deruxtecan (T-DXd) – an anti-HER2 ADC – in patients recruited to the HER2-overexpressing cohort of the phase 2 DESTINY-Lung01 study.